Find generic entry opportunities
Manage your formulary budget
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Crystalline amifostine compositions|
|Abstract:||The present invention relates to a sterile, stable vacuum dried crystalline amifostine composition and, optionally, pharmaceutically acceptable excipient(s). Typically, the crystalline compositions of the present invention exhibit enhanced stability at temperatures ranging from about 4.degree. C. to about ambient temperature for a period of at least 2 years relative to existing solid vacuum dried amorphous amifostine preparations. The reconstituted compositions of the present invention are suitable for administration to humans as a radio- or chemoprotecting agent.|
|Inventor(s):||Kennedy; Paul E. (Phoenixville, PA), Rajewski; Roger A. (Lawrence, KS), Baldoni; John M. (Glenmore, PA)|
|Assignee:||U.S. Bioscience, Inc. (West Conshohocken, PA)|
Patent Claim Types:|
see list of patent claims
|Compound; Dosage form; Composition; Formulation;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||1243272||<disabled in preview>|
|Czech Republic||9500230||<disabled in preview>|
|Czech Republic||284417||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.